ATE279430T1 - Verfahren zur verbesserung der serum halbwertszeit von biologisch aktiven molekülen - Google Patents
Verfahren zur verbesserung der serum halbwertszeit von biologisch aktiven molekülenInfo
- Publication number
- ATE279430T1 ATE279430T1 AT99912297T AT99912297T ATE279430T1 AT E279430 T1 ATE279430 T1 AT E279430T1 AT 99912297 T AT99912297 T AT 99912297T AT 99912297 T AT99912297 T AT 99912297T AT E279430 T1 ATE279430 T1 AT E279430T1
- Authority
- AT
- Austria
- Prior art keywords
- life
- biologically active
- serum half
- improving
- upa
- Prior art date
Links
- 210000002966 serum Anatomy 0.000 title abstract 3
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 abstract 3
- 102100031358 Urokinase-type plasminogen activator Human genes 0.000 abstract 3
- 230000001404 mediated effect Effects 0.000 abstract 2
- 101000638886 Homo sapiens Urokinase-type plasminogen activator Proteins 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 230000001268 conjugating effect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 102000056831 human PLAU Human genes 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7696498P | 1998-03-05 | 1998-03-05 | |
PCT/US1999/004899 WO1999045026A1 (en) | 1998-03-05 | 1999-03-05 | Method for increasing the serum half-life of a biologically active molecule |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE279430T1 true ATE279430T1 (de) | 2004-10-15 |
Family
ID=22135286
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT99912297T ATE279430T1 (de) | 1998-03-05 | 1999-03-05 | Verfahren zur verbesserung der serum halbwertszeit von biologisch aktiven molekülen |
Country Status (6)
Country | Link |
---|---|
US (4) | US6423685B1 (de) |
EP (1) | EP1062230B1 (de) |
JP (1) | JP2002505338A (de) |
AT (1) | ATE279430T1 (de) |
DE (1) | DE69921102T2 (de) |
WO (1) | WO1999045026A1 (de) |
Families Citing this family (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69921102T2 (de) * | 1998-03-05 | 2006-02-02 | Chiron Corp., Emeryville | Verfahren zur verbesserung der serum-halbwertszeit von biologisch aktiven molekülen |
US6887674B1 (en) | 1998-04-13 | 2005-05-03 | California Institute Of Technology | Artery- and vein-specific proteins and uses therefor |
MEP42108A (en) | 1998-10-23 | 2011-02-10 | Kiren Amgen Inc | Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity |
NZ525380A (en) * | 2000-09-18 | 2008-06-30 | Biogen Idec Inc | Non-fucosylated forms of Cripto and their use as tumor blocking agents |
PE20020376A1 (es) * | 2000-09-29 | 2002-05-13 | Abbott Lab | Polipeptidos antiangiogenicos y metodos para inhibir la angiogenesis |
US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
EP1837031B1 (de) * | 2002-06-07 | 2009-10-14 | Waratah Pharmaceuticals, Inc. | Methoden und Kompositionen um Diabetes zu behandeln |
AT413031B (de) * | 2002-08-06 | 2005-10-15 | Stockinger Hannes Dr | Verwendung von cd222 oder eines abgeleiteten peptids zur hemmung von fibrinolyse, zelladhäsion und zellmigration in vitro |
US8129330B2 (en) | 2002-09-30 | 2012-03-06 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
US20040229810A1 (en) * | 2002-10-22 | 2004-11-18 | Antonio Cruz | Gastrin compositions and formulations, and methods of use and preparation |
WO2004060299A2 (en) | 2002-12-26 | 2004-07-22 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of interferon-beta with enhanced biological potency |
RS20050501A (en) * | 2002-12-26 | 2007-08-03 | Mountain View Pharmaceuticals Inc., | Polymer conjugates of cytokines,chemokines,growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
US7553930B2 (en) | 2003-01-06 | 2009-06-30 | Xencor, Inc. | BAFF variants and methods thereof |
US7662915B2 (en) * | 2003-01-18 | 2010-02-16 | Pegsphere Co., Ltd. | Peptides having protected amines of untargeted sites, methods for production thereof and of specifically conjugated PEG peptides using the same |
AU2004220459B2 (en) * | 2003-03-12 | 2010-08-05 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
US7381410B2 (en) | 2003-03-12 | 2008-06-03 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
WO2004091517A2 (en) * | 2003-04-15 | 2004-10-28 | Smithkline Beecham Corporation | Conjugates comprising human il-18 and substitution mutants thereof |
US7261882B2 (en) | 2003-06-23 | 2007-08-28 | Reagents Of The University Of Colorado | Methods for treating neuropathic pain by administering IL-10 polypeptides |
US20050131028A1 (en) * | 2003-09-11 | 2005-06-16 | Pharmacia Corporation | Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders |
US20060228331A1 (en) * | 2003-10-10 | 2006-10-12 | Novo Nordisk A/S | IL-21 Derivatives and variants |
ES2428358T3 (es) * | 2003-10-17 | 2013-11-07 | Novo Nordisk A/S | Terapia de combinación |
AU2005211385B2 (en) | 2004-02-02 | 2008-12-11 | Ambrx, Inc. | Modified human growth hormone polypeptides and their uses |
EP1730196B1 (de) * | 2004-03-12 | 2010-12-22 | Vasgene Therapeutics, Inc. | Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum |
KR20070034465A (ko) | 2004-03-12 | 2007-03-28 | 바스진 테라퓨틱스, 인크. | 혈관형성 및 종양 성장을 억제하기 위한 폴리펩티드 화합물 |
WO2006009901A2 (en) * | 2004-06-18 | 2006-01-26 | Ambrx, Inc. | Novel antigen-binding polypeptides and their uses |
EP1773400A2 (de) * | 2004-07-08 | 2007-04-18 | Amgen Inc. | Therapeutische peptide |
US7638299B2 (en) * | 2004-07-21 | 2009-12-29 | Ambrx, Inc. | Biosynthetic polypeptides utilizing non-naturally encoded amino acids |
ES2529451T3 (es) * | 2004-09-23 | 2015-02-20 | Vasgene Therapeutics, Inc. | Compuestos polipeptídicos para inhibir la angiogénesis y el crecimiento tumoral |
US20080182783A1 (en) * | 2004-10-18 | 2008-07-31 | Novo Nordisk A/S | Growth Hormone Conjugates |
US7816320B2 (en) | 2004-12-22 | 2010-10-19 | Ambrx, Inc. | Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35 |
MX2007007591A (es) | 2004-12-22 | 2007-07-25 | Ambrx Inc | Metodos para expresion y purificacion de hormona de crecimiento humano recombinante. |
MX2007007590A (es) | 2004-12-22 | 2007-12-10 | Ambrx Inc | Composiciones que contienen, metodos que involucran y usos de aminoacidos no naturales y polipeptidos. |
ATE542920T1 (de) * | 2004-12-22 | 2012-02-15 | Ambrx Inc | Modifiziertes menschliches wachstumshormon |
EP1836298B1 (de) | 2004-12-22 | 2012-01-18 | Ambrx, Inc. | Zusammensetzungen von aminoacyl-trna-synthetase und verwendungen davon |
ES2357550T3 (es) * | 2005-04-18 | 2011-04-27 | Novo Nordisk A/S | Variantes de la il-21. |
WO2006125201A2 (en) * | 2005-05-19 | 2006-11-23 | Centocor, Inc. | Anti-biotin-pegylated-mcp-1 mutein antibodies, compositions, methods and uses |
CN103030690A (zh) | 2005-06-03 | 2013-04-10 | Ambrx公司 | 经改良人类干扰素分子和其用途 |
WO2007038395A2 (en) * | 2005-09-23 | 2007-04-05 | Vasgene Therapeutics, Inc. | Use of ephrinb2 directed agents for the treatment or prevention of viral infections |
US20090018029A1 (en) | 2005-11-16 | 2009-01-15 | Ambrx, Inc. | Methods and Compositions Comprising Non-Natural Amino Acids |
US9283260B2 (en) | 2006-04-21 | 2016-03-15 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
SG174781A1 (en) | 2006-09-08 | 2011-10-28 | Ambrx Inc | Hybrid suppressor trna for vertebrate cells |
JP5451390B2 (ja) | 2006-09-08 | 2014-03-26 | アンブルックス,インコーポレイテッド | 脊椎動物細胞内におけるサプレッサーtrnaの転写 |
AU2007292903B2 (en) | 2006-09-08 | 2012-03-29 | Ambrx, Inc. | Modified human plasma polypeptide or Fc scaffolds and their uses |
CN101553501A (zh) | 2006-10-26 | 2009-10-07 | 诺沃-诺迪斯克有限公司 | Il-21变种 |
AU2007336184A1 (en) * | 2006-12-21 | 2008-06-26 | Novo Nordisk A/S | Interleukin-21 variants with altered binding to the IL-21 receptor |
KR101476472B1 (ko) | 2007-03-30 | 2015-01-05 | 암브룩스, 인코포레이티드 | 변형된 fgf-21 폴리펩티드 및 그 용도 |
CA2685596A1 (en) | 2007-05-02 | 2008-11-13 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
EP3127549B1 (de) | 2007-06-22 | 2019-12-18 | Children's Medical Center Corporation | Verfahren und verwendung von einem fragment von saposin a |
NZ584825A (en) | 2007-11-20 | 2013-03-28 | Ambrx Inc | Modified insulin polypeptides and their uses |
JP5702150B2 (ja) | 2008-02-08 | 2015-04-15 | アンブルックス, インコーポレイテッドAmbrx, Inc. | 修飾されているレプチンポリペプチドおよびそれらの使用 |
JP5680534B2 (ja) | 2008-07-23 | 2015-03-04 | イーライ リリー アンド カンパニー | 修飾されているウシg−csfポリペプチドおよびそれらの使用 |
PL2342223T3 (pl) | 2008-09-26 | 2017-09-29 | Ambrx, Inc. | Zmodyfikowane polipeptydy zwierzęcej erytropoetyny i ich zastosowania |
AU2009296267B2 (en) | 2008-09-26 | 2013-10-31 | Ambrx, Inc. | Non-natural amino acid replication-dependent microorganisms and vaccines |
US8293100B2 (en) | 2009-03-13 | 2012-10-23 | Terrasep, Llc | Methods and apparatus for centrifugal liquid chromatography |
WO2010118384A2 (en) | 2009-04-10 | 2010-10-14 | Amylin Pharmaceuticals, Inc. | Amylin agonist compounds for estrogen-deficient mammals |
EP2427204B1 (de) | 2009-05-06 | 2017-04-05 | Janssen Biotech, Inc. | Melanocortinrezeptor-bindende konjugate |
EP2504021A4 (de) | 2009-11-23 | 2013-05-15 | Amylin Pharmaceuticals Llc | Polypeptidkonjugat |
EP2513137B1 (de) | 2009-12-17 | 2018-02-28 | Children's Medical Center Corporation | Aus saposin-a gewonnene peptide und verwendungen davon |
CN104017063A (zh) | 2009-12-21 | 2014-09-03 | Ambrx公司 | 经过修饰的猪促生长素多肽和其用途 |
CN107674121A (zh) | 2009-12-21 | 2018-02-09 | Ambrx 公司 | 经过修饰的牛促生长素多肽和其用途 |
EP2528938A4 (de) | 2010-01-27 | 2013-10-23 | Childrens Medical Center | Proangiogene fragmente von prominin-1 und verwendungen davon |
MX346786B (es) | 2010-08-17 | 2017-03-31 | Ambrx Inc | Polipeptidos de relaxina modificados y sus usos. |
US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
AR083006A1 (es) | 2010-09-23 | 2013-01-23 | Lilly Co Eli | Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas |
EP3170821B1 (de) | 2011-05-27 | 2021-09-15 | Ambrx, Inc. | Zusammensetzungen mit, verfahren mit und verwendungen von mit nichtnatürlichen aminosäuren verknüpften dolastatin-derivaten |
JP6581774B2 (ja) | 2011-05-27 | 2019-09-25 | アンブルックス, インコーポレイテッドAmbrx, Inc. | 非天然アミノ酸結合ドラスタチン誘導体を含有する化合物またはその化合物の溶媒和物、およびドラスタチンアナログを誘導体化するための方法 |
AU2012358269B2 (en) | 2011-12-22 | 2017-11-02 | Children's Medical Center Corporation | Saposin-A derived peptides and uses thereof |
US9611305B2 (en) | 2012-01-06 | 2017-04-04 | Mayo Foundation For Medical Education And Research | Treating cardiovascular or renal diseases |
AU2013270686B2 (en) | 2012-06-07 | 2016-11-10 | Ambrx, Inc. | Prostate-specific membrane antigen antibody drug conjugates |
AU2013270684B2 (en) | 2012-06-08 | 2018-04-19 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
CN104619350A (zh) | 2012-06-14 | 2015-05-13 | Ambrx公司 | 结合到核受体配体多肽的抗psma抗体 |
EP2861262B1 (de) | 2012-06-19 | 2018-11-28 | Ambrx, Inc. | Anti-cd70-antikörper-arzneimittelkonjugate |
DK2863955T3 (en) | 2012-06-26 | 2017-01-23 | Sutro Biopharma Inc | MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF |
EP3919070A1 (de) | 2013-03-14 | 2021-12-08 | Children's Medical Center, Corp. | Verwendung von cd36 zur identifizierung von krebspatienten zur behandlung |
ES2865473T3 (es) | 2013-07-10 | 2021-10-15 | Sutro Biopharma Inc | Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso |
CA2943802A1 (en) | 2014-03-26 | 2015-10-01 | Children's Medical Center Corporation | Cyclic prosaposin peptides and uses thereof |
KR102637699B1 (ko) | 2014-10-24 | 2024-02-19 | 브리스톨-마이어스 스큅 컴퍼니 | 변형된 fgf-21 폴리펩티드 및 그의 용도 |
EP3407917A1 (de) | 2016-01-27 | 2018-12-05 | Sutro Biopharma, Inc. | Anti-cd74-antikörperkonjukate, zusammensetzungen mit anti-cd74-antikörperkonjugaten und verfahren zur verwendung von anti-cd74-antikörperkonjugaten |
SG11201907209QA (en) | 2017-02-08 | 2019-09-27 | Bristol Myers Squibb Co | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
EP3658588A1 (de) | 2017-07-26 | 2020-06-03 | Sutro Biopharma, Inc. | Verfahren zur verwendung von anti-cd74-antikörpern und antikörperkonjugaten bei der behandlung von t-zell-lymphomen |
US10596270B2 (en) | 2017-09-18 | 2020-03-24 | Sutro Biopharma, Inc. | Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates |
PL3849614T3 (pl) | 2018-09-11 | 2024-04-22 | Ambrx, Inc. | Koniugaty polipeptydu interleukiny-2 i ich zastosowania |
JP2022500454A (ja) | 2018-09-17 | 2022-01-04 | ストロ バイオファーマ インコーポレーテッド | 抗葉酸受容体抗体コンジュゲートによる併用療法 |
CN113366015A (zh) | 2018-10-19 | 2021-09-07 | Ambrx公司 | 白细胞介素-10多肽缀合物、其二聚体及其用途 |
CN109400695B (zh) * | 2018-10-31 | 2020-06-30 | 中南大学湘雅医院 | 一种多肽的修饰方法及应用 |
CN113661239A (zh) | 2018-12-28 | 2021-11-16 | 催化剂生物科学公司 | 经修饰的尿激酶型纤溶酶原激活物多肽和使用方法 |
US11613744B2 (en) | 2018-12-28 | 2023-03-28 | Vertex Pharmaceuticals Incorporated | Modified urokinase-type plasminogen activator polypeptides and methods of use |
EP3923991A1 (de) | 2019-02-12 | 2021-12-22 | Ambrx, Inc. | Zusammensetzungen mit sowie verfahren und verwendungen von antikörper-tlr-agonist-konjugaten |
US20220362394A1 (en) | 2019-05-03 | 2022-11-17 | Sutro Biopharma, Inc. | Anti-bcma antibody conjugates |
CN114269749A (zh) | 2019-06-10 | 2022-04-01 | 苏特罗生物制药公司 | 5H-吡咯并[3,2-d]嘧啶-2,4-二氨基化合物及其抗体偶联物 |
CN114746420A (zh) | 2019-06-17 | 2022-07-12 | 苏特罗生物制药公司 | 用于癌症治疗和诊断的作为Toll样受体(TLR)7/8激动剂的1-(4-(氨基甲基)苄基)-2-丁基-2H-吡唑并[3,4-c]喹啉-4-胺衍生物及相关化合物以及其抗体药物偶联物 |
AU2021233909A1 (en) | 2020-03-11 | 2022-09-29 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and methods of use thereof |
KR20230073200A (ko) | 2020-08-20 | 2023-05-25 | 암브룩스, 인코포레이티드 | 항체-tlr 작용제 접합체, 그 방법 및 용도 |
JP2024512775A (ja) | 2021-04-03 | 2024-03-19 | アンブルックス,インコーポレイテッド | 抗her2抗体薬物コンジュゲート及びその使用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4902502A (en) | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
US5089261A (en) | 1989-01-23 | 1992-02-18 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
JPH04218000A (ja) | 1990-02-13 | 1992-08-07 | Kirin Amgen Inc | 修飾ポリペプチド |
IE66205B1 (en) | 1990-06-14 | 1995-12-13 | Paul A Bartlett | Polypeptide analogs |
US5281698A (en) | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
US5362852A (en) | 1991-09-27 | 1994-11-08 | Pfizer Inc. | Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties |
NZ244778A (en) | 1991-10-21 | 1994-03-25 | Ortho Pharma Corp | Peg imidates and protein derivatives thereof |
WO1994006151A1 (en) | 1992-09-08 | 1994-03-17 | Kabushiki Kaisha Komatsu Seisakusho | Method of detecting end point of etching |
AU679945B2 (en) | 1992-09-24 | 1997-07-17 | Chiron Corporation | Synthesis of N-substituted oligomers |
GB9225448D0 (en) * | 1992-12-04 | 1993-01-27 | Erba Carlo Spa | Improved synthesis of polymer bioactive conjugates |
AU7137994A (en) * | 1993-06-01 | 1994-12-20 | Chiron Corporation | Expression of urokinase plasminogen activator inhibitors |
GB9317618D0 (en) * | 1993-08-24 | 1993-10-06 | Royal Free Hosp School Med | Polymer modifications |
DE69921102T2 (de) * | 1998-03-05 | 2006-02-02 | Chiron Corp., Emeryville | Verfahren zur verbesserung der serum-halbwertszeit von biologisch aktiven molekülen |
-
1999
- 1999-03-05 DE DE69921102T patent/DE69921102T2/de not_active Expired - Fee Related
- 1999-03-05 US US09/263,117 patent/US6423685B1/en not_active Expired - Fee Related
- 1999-03-05 AT AT99912297T patent/ATE279430T1/de not_active IP Right Cessation
- 1999-03-05 EP EP99912297A patent/EP1062230B1/de not_active Expired - Lifetime
- 1999-03-05 WO PCT/US1999/004899 patent/WO1999045026A1/en active IP Right Grant
- 1999-03-05 JP JP2000534568A patent/JP2002505338A/ja active Pending
-
2002
- 2002-04-11 US US10/123,092 patent/US7022673B2/en not_active Expired - Fee Related
-
2005
- 2005-04-25 US US11/113,592 patent/US20070060513A9/en not_active Abandoned
-
2007
- 2007-01-31 US US11/701,298 patent/US20070135349A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1062230B1 (de) | 2004-10-13 |
US20070135349A1 (en) | 2007-06-14 |
US20050197297A1 (en) | 2005-09-08 |
JP2002505338A (ja) | 2002-02-19 |
DE69921102D1 (de) | 2004-11-18 |
DE69921102T2 (de) | 2006-02-02 |
US20070060513A9 (en) | 2007-03-15 |
EP1062230A1 (de) | 2000-12-27 |
US20020086819A1 (en) | 2002-07-04 |
US7022673B2 (en) | 2006-04-04 |
US6423685B1 (en) | 2002-07-23 |
WO1999045026A1 (en) | 1999-09-10 |
US20020182705A1 (en) | 2002-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE279430T1 (de) | Verfahren zur verbesserung der serum halbwertszeit von biologisch aktiven molekülen | |
Fulcher et al. | Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V | |
ATE107960T1 (de) | Varianten von menschlichem gewebeplasminogenaktivator sowie verfahren zu deren herstellung. | |
Matsuda et al. | A simple, large scale method for preparation of plasminogen-free fibrinogen | |
DE69816297D1 (de) | Verfahren und zusammensetzungen des gewebefaktors zur koagulation und behandlung von tumoren | |
DE69531741D1 (de) | Verbindungen und zusammensetzungen zur verabreichung aktiver stoffe | |
DE69719359D1 (de) | Cyklische peptide, die an den urokinase-type plasminogen aktivator rezeptor binden | |
YU21399A (sh) | Konjugati koji sadrže delove rastvorljive u vodi, njihova upotreba u proizvodnji leka korisnog za tretiranje raka prostate i farmaceutske kompozicije koje ih sadrže | |
ATE70301T1 (de) | Gewebeplasminogen-aktivator-mutant, dafuer kodierende rekombinante genetische information und verfahren zur herstellung dieser mutanten, deren verwendung und pharmazeutische zusammensetzungen. | |
DK431988D0 (da) | Protein og dna til kodning deraf | |
ATE104863T1 (de) | Pharmazeutische formulierung von plasminogenaktivatorproteinen. | |
Sumi et al. | Higher fibrin-binding and thrombolytic properties of single polypeptide chain-high molecular weight urokinase | |
Lijnen et al. | Mechanisms of plasminogen activation by mammalian plasminogen activators | |
Maksimenko et al. | Water-soluble urokinase derivatives with increased affinity to the fibrin clot | |
Camacho et al. | Limited proteolysis of tumor cells increases their plasmin-binding ability | |
Furlan et al. | Clottability and cross-linking reactivity of fibrin (ogen) following differential release of fibrinopeptides A and B | |
KR900702017A (ko) | 혼성 단백질(bybrid proteins) | |
ATE78292T1 (de) | Plasminogen-aktivator und thrombolytische zusammensetzung. | |
DE69113049T2 (de) | Varianten des gewebeplasminogenaktivators mit vermindertem abbau. | |
NO951219L (no) | Farmasöytisk preparat til behandling av blodklumper og fremgangsmåte til fremstilling derav | |
EP0386240A4 (en) | Novel polypeptide compounds | |
ATE483816T1 (de) | Systemisches virus/ligand genabgabemittel und gentherapie | |
Van Nostrand | Protease nexin II and related protease inhibitors | |
Markland Jr et al. | The Application of a Snake Venom Anticoagulant Enzyme in Burn Therapy. | |
Hall | Assembly of fibrinolysis proteinases on cell surfaces: Plasminogen-cell surface interactions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |